Abstract: This review will focus on the ability of the 2-aminoimidazole to occupy a unique subset of chemical space which makes it an ideal pharmacophore for the development of small molecule collections for discovery based research. These observations rely both on the use of 2-aminoimidazoles as building blocks in medicinal chemistry as well as the recent discovery of alkaloids from sponges of the genus Leucetta which exhibit a diverse range of biological activities around a relatively limited structural core. The preparation of these compounds will also be highlighted.
INTRODUCTION
Much effort has been dedicated to the study of molecular architecture and its relationship to biological activity. From decades of high throughput screening of both natural and synthetic small molecules we have clued in on structural features that impart a high probability of biological efficacy [1] . Recently natural products have enjoyed a renaissance in lead generation for discovery based research. This realization has further been folded into the concept of Biology-oriented synthesis (BIOS) which relies on the core structures of natural products as valuable pre-validated scaffolds [2] . These so-called "privileged" pharmacophores are often the basis of synthetic collections aimed at increasing the success rate of small molecule screening ventures.
In particular, marine natural products derived from sponges have provided valuable leads for therapeutic small molecules [3, 4] . Surprisingly the large majority of these compounds have been isolated from organisms of the class Dermospongiae. In the mid 1980's chemists noted that the other major sponge class, Calcarea, had rarely been subject to chemical investigations. A flurry of efforts through the mid-1990's helped to establish biogenetic relationships among these sponges. Isolated to explore these interconnections and not necessarily for specific biological responses the activities of these natural products have remained largely uncovered. Since these initial investigations, an emerging structural class has recurrently been identified through bioassay guided isolation which contains the 2-aminoimidazole core. From the viewpoint of small molecule discovery this review will highlight alkaloids isolated from Leucetta sp. This small skeletal family has been shown to interrogate an incredibly diverse range of biological processes and thus represents an important discovery scaffold for both medicinal and discovery based research.
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2-Aminoimidazole
In 1958 a nitrogen rich antibiotic, consequently named azomycin, was isolated from a presumptive Streptomyces sp. [5] . This new antibiotic displayed good antimicrobial activity against B. subtilis (6 μg/mL) and E. coli (25 μg/mL) and was relatively well tolerated in mice (LD 50 = 80 mg/kg). Eventually the structure of azomycin was revealed to be 2-nitroimidazole (2) [6] , which along with its synthetic derivative metronadiazole (3) have become clinically relevant antiprotozoal therapeutics ( Fig. 1) [7] . With the parallel observation that several microbes were able to oxidize aromatic amines, Lancini's group showed some Streptomyces species are able to oxidize 2-aminoimidazole itself, along with a series of 4-alkyl-2-aminoimidazoles, to their corresponding 2-nitroimidazoles [8] . This suggested that the 2-aminoimidazole might be the direct biosynthetic precursor to azomycin and in 1970 Okami's group isolated the parent heterocycle (1) from Streptomyces eurocidicus [9] . This study also showed that supplementing the growth medium with L-Arg substantially increased the production of 1, suggesting that arginine catabolism is critical to its biosynthesis. It is unknown whether a similar pathway exists in marine organisms that produce more complex 2-aminoimidazoles, however 1 has been discovered in sponges of the family Halicondriidae [10] . Studies on azomycin's (2) and metronidazole's (3) mechanism of action have revealed that the nitro group is reduced in vivo to the nitroso radical which is responsible for its selective anaerobic antiprotozoal activity [11] . Subsequent studies have shown that hypoxic conditions in tumors are also capable of reducing the 2-nitorimidazole, prompting it to serve as an important prodrug for 2-aminoimidazoles in hypoxic environments [12] [13] [14] .
The 2-Aminoimidazole as a Pharmacophore
In the context of small molecule-protein binding the guanidine is important in the recognition of active site aspartate and glutamate residues. This binding interaction is displayed in the transition state stabilization as seen in chorismate mutase where both Arg7 and Arg116 make twopoint hydrogen bond interactions with the carboxylates of prephenic acid ( Fig. 2A) [15] . Conversely the guanidinium ion of peptidylarginine interacts with protein active site aspartate and/or glutamates by four-point hydrogen bonding. This is seen in the recognition of histone arginines by peptidylarginine deiminase IV (PAD4) (Fig. 2B) [16] . Presumably this four point binding weakens the resonance energy of the guanidinium ion allowing subsequent attack of Cys645 to generate the S-alkylylated thiouronium enzyme intermediate that is subsequently hydrolyzed to give peptidyl citrulline. This hydrogen bond interaction is also an important recognition motif in the coagulation cascade, and has been the basis for the extensive development of guanidine mimetics as thrombin inhibitors [17] .
Given the importance and frequency of this enzymesubstrate recognition motif, it has been mimicked through the development of several important pharmacophores. It has long been recognized two or three nitrogens bonded through a trigonal carbon atom does well to mimic the hydrogen bond donor acceptor pattern of a guanidine [18] . This has led to the application of several common heterocyclic cores to serve as guanidine mimmetics including 2-aminopyridine, 2-aminobenzimidazole, amino-quinazolines, aminooxazoles and thiazoles, some of which are described below [19] .
The 2-aminopyridine has been utilized and can pair with protonated acid residues as seen in the X-ray structure of 2-amino-pyridiniumnicotinate (Fig. 3) [20] . It has also been shown to act as a direct guanidine mimic in the development of non-peptide thrombin inhibitors [21] and in the development of v 3 -integrin antagonists [22] . Modified 2-aminoquinazolines have also provided valuable medicinal leads. With the recent emphasis on discovering small molecule therapeutics for the prevention of Alzheimer's disease, much attention has been focused on inhibiting the membrane bound aspartic protease BACE-1. This enzyme initiates cleavage of the amyloid precursor protein to the -amyloid 1-40(42) peptides which eventually coagulate, promoting the formation of plaques. Through high throughput screening of their corporate collection, researchers at Johnson & Johnson identified the 2-amino-3,4-dihydroquinazoline 4 as a hit structure for the inhibition of BACE-1 (Fig. 4) . Extensive analysis of the binding of 4 to BACE-1 revealed that the substituted guanidine function also made a critical four-point hydrogen bond contact with two Asp residues stabilizing the functional transition state (Fig. 4 inset) .
Further optimization led to compounds 5 and rac-6. It was shown the active enantiomer (S)-6 showed excellent potency against BACE-1 (K i = 11 nM). Further pharmacological studies indicated (S)-6 displayed modest selectivity for BACE-1 over the aspartic proteases renin (IC 50 = 2.7 μM) and cathepsin D (IC 50 = 0.11 μM) as well as the hERG channel (IC 50 = 0.14 μM). However, the measured efflux ratio for (S)-6 of 12.2 suggests that this compound is a P-glycoprotein (Pgp) substrate limiting its availability across the blood brain barrier stalling its advancement.
We believe that the 2-aminoimidazole occupies an important region of chemical space as its hydrogen bond donor-acceptor pattern is capable of recreating that of the guanidine [18] . More importantly, it occupies a unique pKa range between the more acidic 2-aminopyridinium ion [23] and less acidic guanidinium ion [24] (Fig. 5) . Furthermore, the pKa's of 2-aminoimidazolium ions show a predictable trend with substitution, allowing it to be finely tuned for medicinal applications as illustrated in the examples below [25] . This dramatic difference in the pK a of 2-aminoimidazoles (~4 pK a units) with that of guanidine has led to some debate concerning the ability of the 2-aminoimidazole to directly mimic a guanidine. These arguments, based on a lowered pK a and electronic dissimilarity are, however, precisely what makes the 2-aminoimidazole a unique guanidine mimic for medicinal chemistry [25, 26] . Most importantly, their pK a range (pK a ~7-9) allows a significant fraction of compound to be uncharged at physiological pH thus increasing the likelihood of cellular penetration. It also permits this unique heterocycle to cross the blood brain barrier and may decrease the susceptibility of these compounds to Pgp mediated efflux vide infra [27] .
The 2-Aminoimidazole in Appendage Diversity
The 2-aminoimidazole has been utilized as a building block has led to the development of several medicinally relevant small molecules. Researchers at Zeneca delivered a series of broad spectrum antibiotics 7a-c, inspired by the well studied cephalosporins [28, 29] . They were further able to show that substitution on N1 of the aminoimidazole led to inactive compounds, again suggesting that this motif may make an acid hydrogen bond contact (Fig. 6) . Interestingly they were able to correlate the pK a of the 2-aminoimidazole with activity. Against Gram positive organisms they found that a slight elevation in the pK a led to a dramatic decrease in activity. For Gram-negative bacteria, there was little difference, suggesting pK a may alter the membrane permeability.
The resistance of these compounds to -lactamase activity was reversed, with higher pK a derivatives showing significant resistance to hydrolysis, up to a thousand fold more stable than cephaloridine. The introduction of the aminoimidazole also led to a marked increase in oral bioavailability (10-100 fold higher MICs than that of Cefaclor ® in mouse protection tests).
Scientists at Bristol-Meyers Squibb have noted the ability of the 2-aminoimidazole to function as a bioisostere of acylguanidines [30] . Looking to produce novel inhibitors of the sodium hydrogen exchanger-1 (NHE-1) they aimed at replacing the acylguanidine in their lead compounds (13, 14) (Fig. 7) . They surveyed a number of heterocyclic analogues that would conserve the pK a of the acylguanidine as a cationic species, necessary for antagonism of the Na + transporter. Beginning with the dimethylcyclopropyl acids 8a,b, Weinreb amide formation followed by alkylation with either methyl or ethyl-magnesium bromide gave the ketones 9a-d. The -bromoketones were accessed by treating the ketone enolates with N-bromosuccinimide. Condensation of 10a-d with acetylguanidine in DMF gave moderate yields of the acetyl-2-aminoimidazoles 11a-d. These were readily deprotected under hydrolytic conditions with catalytic sulfuric acid to give the 2-aminoimidazoles 12a-d. These compounds showed similar activity against the NHE-1 isoform (i.e. 12d IC 50 = 8 nM) when compared to the lead compound 14 (IC 50 = 6 nM). The authors suggest that the slightly elevated pK a of the 4-methyl-2-aminoimidazole is responsible for the increased activity (i.e. IC 50 = 9 nM for 13 vs. 180 nM for 12c). These compounds also showed similar bioavailability when compared to 13 or 14 (t 1/2 =5 h.; ~26% oral bioavailability). Of many heterocycles that were introduced at this position, including aminopyrazole, diaminopyrimidine, aminothiazole and aminoxadiazole the 2-aminoimidazole most closely mimicked the acylguanidine and approximated the potency of their lead compounds.
Much effort has been dedicated to the development of HIV protease (HIV PR) inhibitors for the treatment of AIDS.
The protease is responsible for the processing of nascent polypeptides to mature proteins comprising the viral particle. Without the formation of the mature particle, viral replication of HIV has been shown to be inhibited. HIV PR has therefore been an active biochemical target for the development of small molecule therapeutics.
Wilkerson and co-workers at DuPont-Merck had developed a cyclic urea-based HIV PR inhibitor scaffold which possessed an acceptable pharmacokinetic profile, but lacking the potency necessary to advance the candidate [31] . Modifications of this scaffold required the preparation of the unsymmetrical urea 18 (Fig. 8) amines were then introduced using Weinreb's amidation conditions (Me 2 AlCl, R 1 NH 2 ) [32] . Reduction of the nitro group with Rainy Ni and hydrolysis of the acetonide afforded 18a,b. Biochemical evaluation of this series of compounds against the HIV PR dimer revealed that 18a and 18b were extremely potent inhibitors K i = 0.023 and 0.012 nM respectively. The compounds were also able to inhibit viral replication in vitro as measured by the ability of the compounds to inhibit RNA synthesis by 90% (18a IC 90 = 13.2 nM; 18b IC 90 = 26.2 nM). Interestingly, QSAR on this series of cyclic ureas suggested the optimum lipophilicity for protease inhibition (ClogP = 4.4) is different from the inhibition of viral replication (ClogP = 6.36) as revealed by the reversal of K i and IC 90 selectivities for 18a and 18b. This makes it difficult to optimize both parameters within the same molecule, but suggests that while 18a,b display the same hydrogen bonding pattern at the terminal urea, the lipophilicity disparity between the 2-aminoimidazole and the benzimidazole has a significant effect on their pharmacokinetic profile.
With these results, 18a and 18b were advanced for pharmacokinetic studies in female Beagles. As seen in the pharmacokinetic profiles (Fig. 8 ) the decreased lipohilicity of 18b had a significant impact on the clearance (CL) and half-life (t 1/2 ) of the compound, advancing its candidacy based on this improved PK profile.
Agents that can stimulate 2 -andrenoceptors modulate a variety of physiological processes including the reduction of blood pressure, sedation and the inhibition of intestinal fluid secretion [33] . Scientists at Allergan Pharmaceuticals targeted the 2 -andrenoceptor to reduce intraocular pressure (IOP), a common condition in patients suffering from glaucoma [34] . The challenge in designing such agents stems from the ability of 2 -andrenoceptor subtypes to modulate different biological processes, most concerning are those in the central nervous system (CNS). One approach to minimizing CNS effect is topical application, minimizing access of the compound to the CNS. From the known 2 -andrenoceptor agonist clonidine (19) [35] , modifications to minimize CNS access generated the lead compounds p-aminoclonidine (20) and AGN-191103 (21) (Fig. 9) . The alternative approach is to discover compounds displaying enough selectivity between the 2 -andrenoceptor subtypes such that they exhibit an enhanced therapeutic index. This led to replacing the imidazolidin-imine with a 2-aminoimidazole. To do so the development of a convenient reagent, carbodiimide 23, was used for the preparation of unsubstituted 2-aminoimidazoles. Treatment of aminoacetaldehyde diethylacetal (22) with cyanogen bromide gave 23 which could be stored without degradation at low temperatures for up to 3 months. Addition of an amine (e.g. 24) to this carbodiimide could be accomplished in the presence of methanesulfonic acid at reflux. Cyclization of the guanidineacetaldehyde diethylacetal (25) using aqueous HCl was followed by neutralization with NaOH to cleanly afforded the 2-aminoimidazole 26. Of the many derivatives prepared in this study, 26 was selected for further evaluation. Binding assays demonstrated 26 bound to the 2A -receptor with a K i = 1.7 nM and was 1200-fold selective for the 2A -receptor over the 1 -receptor, 50-fold selective for the 2A -receptor over the 2B -receptor, and 10-fold selective for the 2A -receptor over the 2C -receptor. Compound 26 was found to be effective in vivo with an EC 50 = 8.7 nM and importantly remained effective when administered intravenously, demonstrating its capability of crossing the blood-brain barrier. Recently there has been interest in developing selective small molecule antagonists of the integrin V 3 with the therapeutic potential for the treatment of osteoporosis, restenosis, angiogenic ocular disorder and cancer [36, 37] . The diversity of integrin mediated signaling and enzyme isotypes, however, demands an exquisite level of selectivity from small molecule antagonists. From the lead compounds 27 and 28 chemists at DuPont aimed at specifically increasing the selectivity of V 3 -mediated adhesion of 293 3 z cells to fibrinogen versus IIb 3 -mediated platelet aggregation. Compound 27 was used essentially as a positive control as it showed selectivity for IIb 3 driven processes. Compound 28, however, displayed modest selectivity and was chosen for further exploration. The first enhancement was delivered by replacing the benzylcarbamate with a trimethylphenyl-sulfonamide (i.e. 29a-d). Next the guanidine function of 28 was altered to explore the role of pKa in selectivity. Targeting the 2-aminoimidazoles with a pK a ~ 8 they prepared compound 29a via a previously unknown reductive amination with N-trityl-2-aminoimidazole. This compound showed potent activity against IIb 3 -mediated platelet aggregation (IC 50 = 15 ± 4.3 nM).
The regioisomeric 2-aminoimidazole 29b was also prepared but showed reduced activity and selectivity suggesting that the orientation of the heterocycle was critical. While maintaing the connectivity of 29a and thus preserving the hydrogen bonding pattern of the guanidine, further lowering the pK a ~4 by acylation. Introducing the aminoimidazole both as the urea 29c and the amide 29d. The aminoimidazole urea 29c retained excellent activity (IC 50 = 34 ± 12 nM) and over 940-fold selectivity. The aminoimidazole amide 29d also showed good activity (IC 50 = 34 ± 12 nM) with a tremendous 3200-fold increase in selectivity.
These examples clearly demonstrates the importance of the 2-aminoimidazole as a building block in medicinal chemistry. Affording chemists the ability to predictably moderate pK a , while maintaining the hydrogen bond donoracceptor pattern of a guanidine, this pharmacophore has been shown to alter activity and selectivity between enzyme isoforms and improve important physiochemical properties such as lipophilicity, blood brain barrier passage, cell permeability and bioavailability.
METHODS FOR THE PREPARATION OF 2-AMINO-IMIDAZOLES
Several methods for the formation of 2-aminoimidazoles are known with widely differing degrees of synthetic utility, but no current method as of yet has a broad range of applicability in complex molecule synthesis. Harsh conditions and/or synthetically difficult and labile precursors are often required. The methods to prepare 2-aminoimidizoles may be categorized into 4 main classes: 1) condensation reactions, 2) ambi-valent addition of 2-aminoimidazole, 3) direct introduction of N-2 and 4) heterocyclic exchange reactions. Functionalized 2-aminoimidazoles can show a wide range of stability issues, the free base of many substrates is susceptible to nucleophilic or base mediated degredation. This instability has thus far precluded a unified strategy to access this heterocycle, but the variety of methods can often lead to success in a complex molecule setting. 
Condensations
By far the most common way to prepare the 2-aminoimidazoles originates with the condensation of an -amino or -haloketone with cyanamide or a guanidine derivative, respectively. This strategy was first disclosed by Norris and McKee who explored the condensation of -aminoacetophenones with N-cyanoguanidines (Fig. 11 , Eq. 1) [38] . Subsequently Lawson was able to show that aminoacetaldehyde diethylacetal can undergo acid catalyzed addition to cyanamide giving the masked guanidine acetaldehyde (Fig. 11 , Eq. 2) [39] . A second acid catalyzed cyclization of the guanidine on the acetal generates the 2-aminoimidazole. As seen in Fig. (9) this strategy has been commonly used and modified for the synthesis of unsubstituted 2-aminoimidazoles.
Kruetzberger found that condensation of 1,2-hydrazinedicarboxamidine with benzoin derivatives in alkali media will yield symmetrically substituted azoimidazoles after spontaneous oxidation of the bis-imidazolhydrazine (Fig. 11 2-aminoimidazole. This methodology is useful but limited to the preparation of 4,5-diaryl substituted 2-aminoimidazoles.
In 1966, Lancini and Lazzari successfully expanded Lawson's strategy to include -aminoketones, including the use of N-alkylamines (Fig. 11 , Eq. 5) [41, 42] . They were the first to observe the strict pH dependence of this condensation. At very low pH the cyanamide is quickly converted to urea. At high pH, dimerization of the aminoketone to the piperazine competes with cyanamide condensation. Having established the optimum pH of the reaction to be ~4.5, these conditions are now routinely adopted. In 1925 Pyman and Burtles had reported the reaction of -bromoacetone and guanidine to give a mixture of uncharacterizable compounds, leading them to abandon this approach and develop their diazonium coupling described below [43] . Seventy years later, Weber discovered that N-acetylguanidine smoothly undergoes displacement and condensation with -haloketones and aldehydes [44] .
Removal of the acetate is completed with hydrazine or catalytic sulfuric acid. This strategy was applied to the synthesis of a number of oroidin derivatives.
The condensation strategies are by far the most common to install the monosubstituted 2-aminoimidazole, common in many complex alkaloids containing this motif. Recently Baran has applied this manifold in the synthesis of sceptrin (32) (Fig. 12 ) [45] . Beginning with the dimethylacetal 30, the -chloroketone could be obtained by treatment with dichloroiodate. Further conversion to the -aminoketone 31 was accomplished by displacement with sodium diformylamide and acid catalyzed hydrolysis of the formaylamine. Following Lancini's protocol both 2-aminoimidazoles were installed simultaneously by condensation with cyanamide to give 32.
Stoltz has also utilized this amino-ketone approach to complete the synthesis of both dramacidin D (36) and F (81) (Fig. 13) serve as progenitor of the -aminoketone. After protecting group manipulations, the nitro group in 34 was reduced with stannous chloride and condensed with cyanamide to give dragmacidin D (36) .
Also targeting dragmacidin D, Jiang utilized Weber's methodology to install the terminal 2-aminoimidazole ( Fig. 14) [50] . The -hydroxyketone 38 was prepared by oxidation and deprotection of the diol 37. The hydroxyl group was then transformed into the bromide 39. Condensation with acetylguanidine in DMF for 4 days gave the aminoimidaozle 40, albeit in moderate yield.
Although these condensation reactions can be optimized to install the 2-aminoimidazole in complex targets, the installation of their amino or haloketones precursor often requires numerous protection and oxidation manipulations, and their stability presents its own challenge.
In the late 1970's Nishimura reported the condensation of substituted diketones with guanidine to yield a variety of useful products (Fig. 15) [51] . This report illuminates the variety of chemistry that is possible around this heterocyclic The condensation of cyanohydrazines with ketones, leading to 2-aminoimidazoles, has been described ( Fig. 16 ) [52] . Methylation of the cyanohydrazone 47a forces tautomerization to the ene-hydrazine 48a, which then undergoes a [3, 3] form the 2-aminoimidazole 50a. While traditional Lewis acids fail to catalyze this process, TMSOTF has proven to be a competent activating agent, leading to the formation of 50b, which is unsubstituted at the N-1 position [53] .
Initially, the scope of this transformation was limited to symmetrical ketones as acyclic aldehydes were poor substrates, leading to complex reaction mixtures and low yields. They discovered that the addition of a nonnucleophilic protic additive increases conversion of acyclic aldehydes ( The application of this methodology to complex substrates has proved limited, as both acid labile functionalities and olefins decompose under these optimized reaction conditions. For access to simple 2-aminoimidazole derivatives, this is an attractive approach as both ketones and aldehydes are readily accessible precursors.
Ambi-valent Addition of 2-Aminoimidazole
Depending on reaction conditions, the parent heterocycle, 2-aminoimidazole, can be influenced to react either at N-2 or C-4. In Potier's synthesis of girolline (54), 2-aminoimidizole was added directly to the -chloroaldehyde 53. Under the influence of sodium carbonate, the imidazole adds preferentially through the 4-position (Fig. 18 , Eq. 1) [54] . As revealed in Horne's synthesis of stevensine (56), methanesulfonic acid was used to add the 2-aminoimidazole across an olefin [55, 56] . Horne has also shown that Friedel-Crafts type alkylation of the activated ethers can proceed with attack by C-4 in the presence of methanesulfonic acid to give stevensine (56) (Fig. 18 , Eq. 2). Alternatively, triflouroacetic acid persuades N-2 addition to give the N-alkylated 2-aminoimidazole 57.
Direct Introduction of N2
As we've seen, condensation reactions are applicable to the preparation of mono-and di-substituted 2-aminoimidazoles. To generate more highly substituted 2-amino- imidazole cores, the direct introduction of N-2 on an appropriately substituted imidazole is frequently applied. The first method for forming 2-aminoimidazoles, in this manifold, was reported in 1925 by Burtles and Pyman who showed that azo-bromoaniline and dimethylimidazole underwent aromatic substitution to form the hydrazone (Fig. 19 , Eq. 1). The aryl hydrazone was then readily reduced by Zn dust and aqueous acetic acid or stannous chloride and hydrochloric acid. Hassner was the first to report the reaction of imidazole lithium with a vinyl azide, hydrolysis of the intermediate triazine gives the aminoimidazole [57] . Since that report, Potier has popularized the use of lithiated imidazoles [58] . Potier reported that lithiation with LDA followed by azide transfer from TsN 3 efficiently generated the 2-azidoimidazoles (Fig. 19, Eq. 2) . Hydrogenolysis of the azide proceeds smoothly to give the 2-aminoimidazole, exemplified in his synthesis of keramidine [59] . Lithiated imidazoles can also be trapped by disulfides to give the 2-thioimidazoles. Oxidation to either the sulfone or sulfoxide creates a leaving group capable of displacement with azide (Fig. 19, Eq. 3) [60] . This strategy has been utilized by Weinreb in the synthesis of ageladine A (74) [61, 62] . To avoid lithiation, Ohta has shown that 2-bromoimidazoles can undergo palladium catalyzed coupling with trimethylsilylazide (Fig. 19, Eq. 4) . Reduction again provides the 2-aminoimidazole. This strategy has been implemented by Ohta's group to access several Leucetta alkaloids discussed below. Also, noteworthy, Ohta has shown that during reduction of the azide it can be directly protected as its benzylidenimine [63, 64] .
Heterocyclic Exchange Reactions
The transformation of 3-amino-1,2,4-oxadiazoles (i.e. 58) to 2-aminoimidazoles can be carried out by reaction with fluorinated -dicarbonyls to give the -hemiaminal 60 (Fig.  20) [65] . This can undergo subsequent conversion to the 2-amidoimidazole through a Boulton-Katritzky Rearrangment (i.e. to give 63. The benzamide can also be removed via acid catalyzed hydrolysis to give the trifluoromethyl aminoimidazole 64. An interesting reaction, however the synthesis of the intermediate -enaminocarbonyl is low yielding and initial results suggest limited substituent scope, as the initial condensation requires the presence of the trifluoromethyl ketone.
Van der Eycken has recently reported condensation of -bromoketones to form substituted imidazol-pyrimidinium salts (e.g. 66) (Fig. 20) [66, 67] . This pyrimidinium salt can undergo transamination with hydrazine under microwave irradiation to free the 2-aminoimidazoles, providing rapid access to N-2, C4, C5-trisubstituted aminoimidazoles (67). The current proposed mechanism for the hydrazine or secondary amine deprotection of the imidazol pyrimidinium salt is the conjugate addition of the amine to the pyrimidine ring followed by sigmatropic rearrangment to an azabutadiene intermediate. Replacing hydrazine with morpholine, this azabutadiene intermediate could be isolated in good yield. Protonolysis of the azabutadiene followed by 1,4-addition of a second amine equivalent initiates release of the 2-aminoimidazole and diazapentadienium salt. Methodology to prepare 2-aminoimidzoles has greatly advanced due to the rising demand in natural product synthesis and medicinal chemistry. However, the development of methods to succinctly generate a highly functionalized 2-aminoimidazole core from stable precursors is warranted.
2-AMINOIMIDAZOLE ALKALOIDS FROM DERMO-SPONGIAE
Alkaloids derived from marine sponges of the class Demospongiae introduced us to the existence of the 2-aminoimidazoles in the marine environment. From simple biogenetic precursors (i.e. oroidin (70) and hymenidine (71)) over 60 pyrrole-imidazole natural products have been isolated (Fig. 22) [68] . The ambi-valent reactivity of the 2-aminoimidazole has been an inspiration to synthetic chemists for decades, and has pinnacled with the synthesis of many of more complex derivatives i.e. 32, 36, 78, 80 and 81. The chemistry of this family of natural products has recently been compiled in an excellent review by Weinreb [69] .
ACTIVITY OF DERMOSPONGIAE ALKALOIDS
There have been a number of recent accounts regarding the activity of these alkaloids that further illustrate the 2-aminoimidazole to be an important pharmacophore embedded in these small molecules. The discovery of bacterial communities (biofilms) which posses increased resistance to antibiotic therapies has generated a great deal of interest to identify small molecules that can interrupt their formation or preferably disrupt their aggregation. A particularly troubling microorganism, Pseudomonas aeruginosa often exists in the biofilm state and is responsible for hospital borne infections in immunocomprimised patients. To date very few small molecule scaffolds have proven capable of modulating biofilm formation. Of those few, both bromoagileferin (79) and oroidin (70) have been identified as agents capable of disrupting bacterial attachment and organization [70] . Aiming to identify the minimal structural units responsible for the biofilm inhibitory activity of 79, Melander and co-workers made several minimized analogues (Fig. 23) [71] . Beginning with the trans-diol 82, bismesylation and displacement with sodium azide gave 83. Epoxidation and ring opening with sodium azide at elevated temperatures gave the tris-azide 84. All three azide functionalities were smoothly reduced and globally protected as their t-Boc carbamates. Oxidation of the secondary alcohol with PDC afforded the stable -aminoketone 85. After deprotection of the amines with TFA and salt exchange, the hydrochloride salt of the -aminoketone could be condensed with cyanamide to give the 2-aminoimidazole 86. In a similar manner, the 2-aminoimidazole 87 bearing a cis-aminomethyl arrangement was also prepared. When assayed for their ability to inhibit biofilm formation of two Pseudomonas aeruginosa strains (PA01 and PA14) both 86 and 87 showed similar moderate activity (IC 50 = 100-200 μM) while the known 4-(3-aminopropyl)-2-aminoimidazole (88) showed no significant inhibition. To further understand the underlying mechanism for the activity of 86 and 87, they assessed their activity against planktonic P. aeuginosa prior to biofilm formation. Interestingly, 86 and 87 displayed differential toxicities, suggesting that the activity of 87 may be due to both bactericidal and biofilm inhibition activity.
In attempts to enhance the activity of these 2-aminoimidazole derivatives toward the inhibition of biofilm formation, Melanader has recently developed a series of reverse amide oroidin analogues 89a-d (Fig. 24) [72] . Compounds in the series bearing a long alkyl chain on the amide portion (89a-d) showed a predictable increase in potency as dependent on chain length. The dodecyl-analogue 89d showed good activity at inhibiting the formation of both PA01 and PA14 biofilms with IC 50 = 2.84 and 2.26 μM respectively. Noting that chronic infections are often a result of established biofilms, it is also therapeutically necessary to discover small molecules capable of dispersing biofilms.
Compound 89d was found to have potential against established biofilms of both PA01 and PA14 with EC 50 = 32.8 and 21.3 μM respectively. These compounds present an opportunity both for therapeutic intervention and as tools to study the underlying mechanism of biofilm formation and dispersion. Oroidin has recently been shown to inhibit enoyl reductases from P. falciparum, M. tuberculosis and E. coli [73] . It is unclear whether this activity may be partially responsible for oroidin's ability to disrupt biofilm formation.
Girroline (54) was originally isolated from specimens of Pseudaxinyssa canthranella collected around New Caledonia. It was subsequently shown to have significant cytotoxic activity, inhibited exponentially growing leukaemic cells, and had significant activity in several models of grafted murine tumors [74] . It was subsequently moved to Phase-I clinical trials where the acute cardiovascular toxicity of the compound was discovered [75] . Further studies on girroline's mechanism of action suggested that it inhibited protein synthesis in leukemic cells [74] . This was confirmed and shown to be a result of disruption of nascent polypeptide release (termination), not by interfering with initiation or elongation [76] . Recently 54 was revealed to cause G2/M cell-cycle arrest and the accumulation of polyubiquitinated p53 [77] . Following this observation, the effect of 54 on translation has recently been questioned as girroline causes both a dose-and timedependent arrest of cells in the G2 phase, explaining the decrease in protein synthesis. Also suggesting that it might be acting through a p53 independent mechanism to control the G2/M checkpoint [78] .
Ageladine A (74) was isolated from the sponge Agelas nakamurai from bioassay guided fractionation efforts to discover new matrix metalloproteinase 2 (MMP-2) inhibitors [79] . These zinc-dependent proteinases are critical for tumor growth and metastasis through the regulation of angiogenesis [80] . It was shown that 74 is able to non-competitively inhibit MMP-2 (IC 50 = 2.0 μg/mL). Interestingly, 74 had no Zn 2+ chelating ability which is the typical modus operandi for MMP inhibitors. It was further shown to be capable of inhibiting several other MMP isoforms including MMP-1,8,9,12, and 13 with IC 50 values of 1.2, 0.39, 0.79, 0.33, and 0.47 μg/mL respectively. The antiangiogenic effect of ageladine A was evaluated by the in vitro vascular organization model using mouse ES cells. Vascular formation was significantly inhibited at 10 μg/mL. The preparation of various derivatives of 74 indicated that both bromines on the pyrrole ring and an unsubstituted 2-aminoimidazole were critical for activity [81] . Attesting to the ability of small molecules carrying the 2-aminoimidazole to be membrane permeable, ageladine A has recently been exploited as a pH sensitive dye possessing fluorescence changes capable of reporting small intracellular pH changes induced by extracellular acidification [82] .
2-AMINOIMIDAZOLES FROM CALCAREA
As mentioned previously, the early to mid-1980's saw the realization that sponges of the class Calcarea had largely been overlooked as a source of natural products. Having collected specimens off the coast of Bermuda (Class: Calcarea; Leucetta microraphis) Cardellina and Meinwald isolated a nitrogenous minor metabolite from this sponge, leucettidine (90) (Fig. 25) [83] . Lacking the usual C2-amino group, this pteridine analogue suggested that this class of sponge might be host to unusual marine alkaloids and vitalized the study of the class as a source of novel metabolites.
From the viewpoint of small molecule discovery, we are impressed by the naamidine-type alkaloids ability to interact with a very diverse range of biological processes. Considering the structural similarity within this family, we believe the diversity in activities is due to the presence of the 2-aminoimidazole and all of its properties described above. Constructed around the 2-aminoimidazole core, these alkaloids can roughly be categorized into four groups as related by successive biosynthetic condensation/oxidation reactions:
1)
Category I: those which are unfunctionalized on the 2-amino group of the A-ring (ring diversity: AB, ABC, and ABE)
2) Category II: those which are functionalized on the 2-amino group usually with a hydantoin group comprising the D ring. (ring diversity: ABD, ABCD and ABDE)
3) Category III: those in which benzylic oxidation between the A and B rings construct fused tetracyclic systems (ring diversity: ABC)
4)
Category IV: those in which the A-ring is oxidized to the 2-amino-imidazolone (ring diversity: AB, ABC)
Category I: Leucetta 2-Aminoimidazoles
Several years after the isolation of leucettidine (90), while investigating samples of Leucetta chagosensis from the bay of Na'ama, Carmely and Kashman isolated the first 2-aminoimidazole natural products from this genus [84] . They isolated two category I alkaloids, naamine A (91) and isonaamine A (99) (Fig. 27) . The biosynthetic relationship between the naamines and the isonaamines remains a mystery. Noting that the naamines are potentially the result of phenethylamine dimerization, it is unclear whether they are biosynthesized by different routes or whether a 1,2-alkylshift occurs to generate the benzylamine portion of the isonaamines. This sponge also produces naamine B (92), which along with N,N-dimethyl naamine D (95) are dimethylated [85] . It wasn't until 1997 that Schmitz and co-workers isolated Naamine C (93) from samples of L. chagosenis collected in Micronesia [86] . Isonaamine B (100) was also isolated from specimens of L. chagosensis collected from Yap, Micronesia [87] . Interestingly it is methylated on N-3 similar to naamine B and N,N-dimethylnaamide D.
Naamine D (94) was isolated form L. chagosensis and shown to be unmethylated on the 2-aminoimidazole ring [88] . Further, 94 was shown to be a modest inhibitor of inducible nitric oxide synthase (iNOS), demonstrating a 50% reduction in nitric oxide production at 1.0 mM. It was also demonstrated inhibition was competitive as the addition of 1.0 mM L-arginine fully regenerated nitric oxide production. Although the exact mode of naamine D binding to iNOS has not been elucidated it does suggest that this heterocycle may emulate protein binding by arginine substrates. Naamine D was also shown to be active against the opportunistic pathogen in AIDS patients, Cryptococcus neoformas (MIC = 6.25 μg/mL).
In attempts to extensively classify Leucetta species based on their metabolite profiles, Crews and co-workers examined nine different Indo-pacific collections [89] . One specimen of L. avocado produced N,N-dimethyl naamine D (95) , that was found to be mildly active against an antimicrobial panel consisting of E. Coli, S. aureus., B. subtilis. and C. albicans. Several other species were found not to produce 2-aminoimidazole alkaloids. Examination of L. chagosensis collected from the Great Barrier Reef resulted in the isolation of two category I alkaloids, naamine E (96) and isonaamine C (101) [90] . Isonaamine C was found to be cytotoxic to a variety of cell lines; GI 50 's: HMO2 (5.3 μg/mL), HepG2 (2.2 μg/mL) and Huh7 (2.1 μg/mL).
Ohta has completed the synthesis of isonaamine A (99)
en route to the isonaamidines described below (see Fig. 43 ). Van der Eycken has very recently described the use of his imidazopyrimidinium methodology to access both isonaamine A and C and numerous analogues (Fig. 28) [91] .
Addition of p-methoxybenzylamine to 2-chloropyrimidine gave the substituted 2-aminopyrimidine 105.
Concurrently the -bromocinnamaldehydes 106a,b were prepared from the cinnamic acids by reduction, oxidation and bromination with dibromobarbituric acid. Condensation of the two partners under microwave irradiation gave the imidazopyridinium bromides 107a,b. Transimination of 107a with hydrazine gave 108 which upon demethylation with boron tribromide gave isonaamine A (99). Intermediate 107b afforded isonaamine C (101) directly after treatment with hydrazine. Naamines F (97) and G (98) were isolated from specimens of L. chagosensis collected in Indonesia [92] . Naamine G was found to be strongly antifungal against Cladosporium herbarum (20 mm Zone of Inhibition at 20 μg/disk). It was also found to found to be cytotoxic to both mouse lymphoma cell lines (46% growth inhibition at 10 μg/mL) and human cervix carcinoma (HeLa) lines; (29% growth inhibition at 10 μg/mL).
The mono-benzylsubstituted alkaloid dorimidazole A (102) was isolated from an indo-pacific nudibranch, Notodoris gardineri [93] .The structure of 102 was confirmed by synthesis (Fig. 29) . It is known that this nudibranch preys on L. chagosensis and may well accumulate these aminoimidazoles as a result of this predation, as both naamine A and isonaamine A have also been found in both the sponge and its associated nudibranch, Notodoris citrine [85] . Under similar pretenses as dorimidazole A, preclathridine (103) was isolated from the nudibranch Notodoris gardineri [94] . One of the early syntheses of these marine 2-aminoimidazole natural products was accomplished in 1996 when Ohta completed the first total synthesis of preclathridine A (103) [95] . Ohta sought to install a 2-amino group onto the imidazole ring by first converting a 2-bromoimidazole to a 2-azidoimidazole and then subsequently reducing the azide group to give the desired 2-aminoimidazole. Ohta's model study (Fig. 19, Eq. 4) suggested that converting the bromoimidazole to the azidoimidazole could be accomplished using TMS-azide and PdCl 2 (PPh 3 ) 2 . Hydrogenation of azide then gave the desired 2-aminoimidazole. with NBS to give 114 in near quantitative yield (Fig. 30) . Bromoimidazole (114) was then subjected to lithiumhalogen exchange using t-BuLi and followed by addition to piperonal giving alcohol 115. Desulfurization with Raney nickel gave a mixture of the desired sulfide 116a in 21% yield which possessed the C4 sulfide to block bromination in the subsequent reaction. The major product of the desulfurization was the imidazole 116b, formed in 36% yield. Installation of the 2-amino group onto the imidazole ring began with the bromination of sulfide 116a with NBS to give bromide 117. Conversion of the bromide to azide 118a proceeded under optimized conditions (PdCl 2 (PPh 3 ) 2 , TMS-azide) in a relatively low 38% yield, with an additional 8% yield of the related azaphosphorane 118b. Hydrogenation of azide 118a followed by removal of the thiophenyl group then gave preclathridine A in 42% yield over two steps. Thus Ohta's synthesis of preclathridine A was accomplished in 7 linear steps in 2.2% overall yield.
In the same report disclosing the synthesis of isonaamine A and C, Van der Eycken also demonstated the rapid preparation of both preclathridine and dorimidazole A (Fig. 31 ) [91] . Beginning with the -bromo-cinnam-aldehydes 119a,b condensation with 2-N-methylpyrimidine (120) gave the imidazopyrimidinium salts 121a,b. Further irradiation of these intermediates in the presence of hydrazine hydrate gave the 2-aminoimidazoles preclathridine (103) and OMe-dorimidazole (122) . Demethylation of 122 with boron tribromide gave dorimidazole in 71% yield.
The important role of leukotrienes in inflammation, and the relevance of leukotriene signaling as a therapeutic target Fig. (31) . Van der Eycken's synthesis of preclathrine and dorimidazole.
to treat a variety of diseases including gout, asthma and inflammatory bowel disease has been well established [96] . Scientists at Smithkline Beacham initiated a screen aimed at identifying novel Leukotriene B 4 (LTB 4 ) antagonists from natural sources [97] . The initial assay was designed to exploit competition between [ 3 H]-LTB 4 and natural product fractions with membrane bound receptors. Bioassy guided fractionation of extracts of the Palauan sponge Leucetta microraphis delivered an active fraction containing leucettamine A (104), leucettamine B (105) and a minor metabolite leucettamidine (176). Interestingly leucettamidine carries the iminohydantoin. Further purification revealed that lecettamine B was essentially inactive in the assay even at concentrations greater than 100 μM. Leucettamine A and leucettamidine, however, were both capable of antagonizing LTB4 binding to its receptor (IC 50 = 4.0 and 15.6 μM respectively). Further evaluation of leucettamine A in human U937 cells showed that it had high affinity (IC 50 = 0.75 μM) for the receptor. The compound was shown to block the LTB4-induced Ca 2+ transient (IC 50 = 4.6 μM), specifically, suggesting that 104 is a pure antagonist of the membrane bound LTB4 receptor.
Subsequent medicinal chemistry efforts were aimed at improving the potency of 104 [98] . Ultimately the condensation of cyanamide with an -aminoketone was used to prepare these leucettamine derivatives. To access 2-aminoimidazoles which are symmetrically substituted at the C-4 and C-5, Boehm and co-workers relied on the intermediacy of an aminoalcohol derived from a symmetrically substituted epoxide (Fig. 32) . Thus Wittig reaction of the homobenzylic phosphonium salts 124a,b with appropriately substituted arylacetaldehydes 123a,b provided a mixture of E and Z olefins. Epoxidation of the alkene gave 125a,b as an inconsequential mixture of epoxide diastereomers, as the stereocenter would later be destroyed upon forming the aminoimidazole. Ring opening of the epoxide with either methylamine or n-hexylamine gave the aminoalcohols 126a,b. Attempts to directly oxidize the alcohol and condense the amino ketone with cyanamide led to very low yields of the 2-aminoimidazoles. Noting that the free base of the amino ketone was unstable, presumably dimerizing to the pyrazine, they first protected the secondary amine as its t-butylcarbamate. Oxidation of the protected amino alcohols with PDC proceeded smoothly to give 127a,b. The hydrochloride salts of the aminoketones were found to be stable after acid-catalyzed removal of the Boc group. Subsequent condensation with cyanamide under Lancini's conditions afforded leucettamine A (104) and the n-hexyl substituted derivative 128, lacking the methylenedioxy groups on the aromatic rings.
In order to access leucettamine analogues that carry different substitution on the aromatic groups Boehm turned to the preparation of unsymmetrical amino ketones from N-methylated amino acid derivatives 129a-d (Fig. 33) . Weinreb amide formation and reaction with an appropriate Grignard reagent gave the protected amino ketones 130a-d in moderate yields. Similar to the reaction sequence for the conversion of 127b 104 the 2-aminoimidazoles 131a-d were obtained.
In general they noted that the dioxolanes are important for receptor binding. They were, however, also taken with the idea that the 2-amino group might be mimicking the LTB 4 12-hydroxyl group (Fig. 34) . Thus they prepared analogue 132, via deprotection of 131d, where the hydroxy chain mimics the C-1 carboxyl group of LTB 4 . They observed that 132 was comparable to 104 in its affinity for the LTB 4 receptors in intact U-937 cells (K i = 2.4 μM). The ability of 132 to induce Ca 2+ mobilization in PMNs was also examined, and analogous to Leucettamine A, it was not an agonist even at concentratiouns up to 100 μM. The concentration dependent inhibition of the LTB 4 -induced calcium transient by 132 (IC 50 = 6.2 μM) and leucettamine A are quite similar.
Category II: Leucetta 2-Aminoimidazoles
The naamidine alkaloids are further functionalized at N-2, generally with a modified hydantoin (Fig. 35) . Naamidine A (133) and Isonaamidine A (171) were reported in the initial isolation of 2-aminoimidazoles from L. chagosensis [84] . Naamine A (133) received considerable attention after Ireland reported that it antagonizes epidermal growth factor receptor-stimulated DNA synthesis, and inhibited the growth of implanted squamous cell tumors in nude mice. [99] These antimitogenic effects were pronounced in vitro as 133 completely inhibited the synthesis of DNA at 0.78 μM. Isonaamidine B and C were also active, albeit at higher concentrations. The over expression of EGFR has been shown to occur in a number of human cancers, including a number that often have poor prognosis. Additional research by Ireland [100] also showed that naamidine A at low μM concentrations cause cells to arrest in the G 1 phase of the cell cycle. Intriguingly, naamidine A is the first small molecule that has shown this effect on EGF kinases and consequent G 1 cell cycle arrest, and therefore potentially leading to a new class of chemotherapeutic drugs, although the exact target of 133 has yet to be elucidated. This insight into the therapeutic potential of these alkaloids initiated synthetic efforts toward the naamidines. The first total synthesis of naamidine A and its presumed Fig. 30 ) [101] . Ohta began the synthesis of naamidine A with 1-methyl-2-phenylthio-1H-imidazole, and then sequentially functionalized the imidazole ring through a series of selective lithiation/addition reactions (Fig. 36) . Thus, thiophenyl substituted imidazole 148 was first selectively lithiated with t-BuLi and followed by the addition of MOM protected p-hydroxybenzaldehyde to give alcohol 149. The newly formed hydroxyl group was then protected as its TBS-ether. Next, bromination of the 4-position of the imidazole ring was then accomplished by the use of N-bromosuccinimide to give 150. Lithium-halogen exchange using t-BuLi was then followed by the addition of p-methoxybenzaldehyde to give the tetrasubstituted imidazole 151 as an inconsequential 1:1 mixture of diastereomers. Desilylation of the TBS-ether with TBAF in THF gave diols 152. Reduction of the thiophenol group with nickel (II) chloride occurred to give 153 with a significant amount of the mono-deoxygenated products 154. Deoxygenation of the carbinols with zinc powder in concentrated HCl/AcOH then gave the deprotected phenol which subsequently was reprotected as its TBS-silyl ether to give 155.
Selective bromonation at the 2-position of the imidazole with NBS gave the bromide which was followed by lithium/halogen exchange then addition to trisly azide to give 2-azidoimidazole 156. Hydrogenolysis of the azide yielded 2-aminoimidazole. Deprotection of the phenolic TBS ether with TBAF gave the natural product naamine A (91) . Conversion of 91 to naamidine A (133) was accomplished in 44% yield by the selective condensation of 1-methylparabanic acid in the presence of TMSCl/Et 3 N. Ohta completed the total synthesis of naamidine A in 13 linear steps with an overall 1.2% yield.
The second total synthesis of naamidine A was accomplished by Watson in 2006 [102] . In contrast to Ohta's use of a partially functionalized imidazole ring, Watson created the 2-aminoimidazole core by condensation of an -aminoketone with cyanamide (Fig. 37) . Watson began the synthesis of naamidine A with a selective N-methylation of the commercially available Boc protected amino acid 157. Using conditions developed by Benoiton [103] , Watson saw no methyl ester formation, forming exclusively the acid 158. Methylation of the amine was essential to install the required regiochemistry in the ring. Formation of the Weinreb amide 159 was accomplished by in situ formation of the acid fluoride followed by the addition of N,O-dimethylhydroxyamine [104] . Addition of metallated p-methoxybenzyl chloride gave the ketone 160. Removal of the Boc group was accomplished using 4M HCl and the resulting suspension was then condensed with cyanamide [105] to give the trisubstituted 2-aminoimidazole. Hydrogenolysis of the benzyl group gave naamine A (91). Installation of the dehydrohydantoin was accomplished using Otha's regioselective condensation procedure, thus 1-methyl-parabanic acid was first silylated with N,O-bis (trimethysilyl)acetamide (BSA), which was then reacted with 91 to give 133 in 80% yield. Watson's synthesis of naamidine A was accomplished in 6 linear steps and 35% overall yield.
The intriguing activity and the relatively low molecular weight of these 2-aminoimidazole natural products have made them quite amenable to analogue synthesis. In 2007, Watson made a series of analogues in an effort to elucidate structure-activity relationships of naamidine A (133) [106] . By comparing the IC 50 values of a series of deletion analogues against those of naamidine A, Watson was able to determine the role of the three major subunits that are attached to the central 2-aminoimidazole core. The C 2 -dehydrohydantoin deletion analogue of naamidine A is the known natural product naamine A (91) (Fig. 38) . The markedly decreased ability of naamine A to inhibit EGFR stimulated DNA synthesis (IC 50 = 75 μM) indicates that the dehydrohydantoin is a necessary component for naamidine's A activity. The C 5 -deletion analogue 162 of naamidine A is structurally quite similar to the known natural product clathridine A (177), which has been shown to be only weakly cytotoxic against a number of cell lines. As a result, the exact C 5 -deletion analogue was assumed to have similarly low cytotoxicity and thus was not prepared.
As the C 4 -deletion analogue was not known, Watson set out to synthesize 161 beginning with the LiAlH 4 reduction of the previously prepared Weinreb amide 159 [102] to give aldehyde 163. Next, removal of the N-Boc group under acidic conditions gave an intermediate hydrochloride salt which was then condensed with excess cyanamide to give the desired 2-aminoimidazole 164. Cleavage of the benzyl ether under hydrogenation conditions was followed by installation of the dehydrohydantoin tail via the method of Ohta to give C 4 -deletion analogue of naamidine A, 161. The ability of 161 and 133 to inhibit EGFR mediated DNA synthesis were essentially identical (IC 50 = 4 and 3 μM respectively), suggesting that the C4-methoxybenzyl group is unnecessary for activity.
Replacing the 2-aminoimidazole core, Watson synthesized a small series of 2-aminothiazoles to determine the importance of this heterocyclic core on the biological activity of naamidine A. The synthesis of 2-aminothiazole analogues began with the selective protection of the commercially available phenol 165 followed by oxidation of the primary alcohol under Dess-Martin conditions to give aldehyde 166. Treatment of this aldehyde with potassium cyanide in the presence of sodium bisulfite gave cyanohydrin 167. Conversion of 167 to the requisite -hydroxyketones began by in situ protection of the hydroxyl group with TMSOTf/Et 3 N followed by addition of appropriate Grignard reagent to give 168a-c. The -hydroxyketones were next converted to the corresponding -bromoketones with SOBr 2 conditions then condensed with thiourea. Deprotection of the benzyl ethers using BCl 3 afforded 2-aminothiazoles 169a-c. Installation of the dehydrohydantoin then followed using the same procedure as was used to prepare the naamidine analogues, giving 170a-c.
Watson's SAR data for the thiazole analogues shows replacing the 2-aminoimidazole with a 2-aminothiazole core decreases potency of these analogues (Fig. 41) . The direct thiazole analogue of naamidine, 170 (IC 50 = 10 μM), is only slightly less active than 133 (IC 50 = 3 μM), suggesting that the N-1 methyl group of the 2-aminoimidazole is not engaged in any interaction with the target. It is interesting to note that while the presence of the dehydrohydantoin tail in this series of analogues increases the activity of the compounds in comparison to the pimary N-2 amine, the effect is noticeably less than in the 2-aminoimidazole analogue series.
It is difficult to offer precise structure activity relationships among these analogues, due to the resolution of the assay and the lack of a defined biochemical target. Naamidine A represents an important tool, not only as a potential chemotherapeutic, but also as a novel probe to study ERK phosphorylation and its role in EGFR signaling. Naamidines B-D (134-136) were isolated from L. chagosensis along with naamine B and display a diverse range of methylation patterns around both the imidazole and the modified hydantoin [85] . Naamidines E (137) and (138), along with clathridine C (179, Fig. 42) were isolated from Leucetta sp. and its associated nudibranch Notodoris gardineri [107] . Naamidine F (138) is the only known alkaloid of this family to have the C-ring at the quinone oxidation state. Naamidine G (139) was isolated for Leucetta specimens collected in the Coral Sea [108] . Accompanying 139 were the naamidines (143-147) with oxidized benzylic side chains. These biosynthetic links, suggest that the category III alkaloids may be derived from intramolecular carbocyclization on a benzylic cation derived from such oxidized metabolites. Naamidines H (140) and I (141) were isolated from Indonesian collections of L. chagosensis [109] . Naamidine H showed moderate cytotoxicity against HeLa cells (IC 50 =5.6 μg/mL). Naamidine I, further modified with an N-Me imino group on the modified hydantoin showed slightly weaker cytotoxicity (IC 50 = 15 μg/mL). Pyronaamidine (142) was isolated from Micronesian collections of Leucetta sp. by Scheuer and Clardy [110] . It was shown that 142 is cytotoxic to KB cells with an MIC = 5 μg/mL.
Akin to the 1,2-alkyl shift that differentiates the naamine and isonaamine series, the isonaamidines (171-175) have been isolated from Leucetta sp (Fig. 42) which display a similar skeletal rearrangement. Isonaamidine A (171) was isolated in Carmely and Kashman's initial report of alkaloids from L. chagosensis [84] . The monomethylated variant isonaamidine B (172) was reported in their follow-up communication [85] . Isonaamidine C (173) was isolated from Fijian collections of Leucetta sp. along with 172 and 133 in the initial report of bioassay guided fractionation for the inhibition of EGF mediated mitogenesis [99] . Isonaamidine D (174) was co-isolated with isonaamine B [87] , noted to have modest antifungal activity against Aspergillus niger (MIC = 100 μg/mL). Isonaamidine E (175) was co-isolated with naamine E and isonaamine C [90] . Isonaamidine E was found to be cytotoxic to a variety of cell lines; GI 50 's: HMO2 (7.0 μg/mL), HepG2 (7.0 μg/mL) and Huh7 (1.3 μg/mL). Exploiting his ability to prepare the naamidine alkaloids, Ohta completed the synthesis of both isonaamidines A and C (Fig. 43) [111] . Ohta chose to use metallation/alkylation chemistry to decorate the imidazole ring, as applied in the synthesis of naamidine A (133). In this synthesis Ohta also introduces a much improved procedure for installation of the pendant hydantoin tail.
Ohta began the synthesis of isonaamidines A and C with the selective lithiation of sulfide 181 using n-BuLi, followed by addition of p-anisaldehyde to give alcohol 182 (Fig. 43) . Deoxygenation of the benzylic alcohol was accomplished by the procedure of Kobayashi, [112] thus alcohol 182 was reduced with triethylsilane in the presence of trifluoroacetic acid to quantitatively yield the 5-benzylimidazole 183. The sulfide was reduced with NaBH 4 in the presence of nickel(II) chloride to give imidazole 184 [113] . N-3 Alkylation of the imidazole 184 with p-methoxybenzylbromide gave the imidazolium salt 185 as a precipitant in nearly quantitative yield. Hydrolysis of the SEM group using 10% aqueous HCl gave the 1,4-di(4-methoxybenzyl)imidazole 186.
Installation of the 2-amino group was then accomplished in three steps. First, the imidazole was brominated using NBS to give 187, which was followed by lithium-halogen exchange using t-BuLi and addition of trisyl azide. Reduction of the azide group with H 2 over Pd-C gave the precursor for isonaamidine C, 188, in 62% yield from the bromide 187.
At this point, demethylation of 2-aminoimidazole 188 with boron tribromide gives isonaamine A 99 in quantitative yield. Isonaamidines A 171 and C 173 were finally obtained from 99 and 188, respectively, by treatment with 1-methyl-3-trimethylsilylparabanic acid. Thus Ohta completed the total synthesis of isonaamidine A and isonaamidine C in 8 linear steps in 28% overall yield and 9 linear steps in 25% overall yield, respectively. Several other naamidine-type alkaloids have been isolated 176-180 (Fig. 42) . Leucettamidine (176) was co-isolated with leucettamine A (104) [96] . The first of a family of naamine-type alkaloids carrying the dioxolane moiety, clathridine (177), was isolated from Mediterranean collections of the related marine sponge Clathrina clathrus [114] . It was shown that 177 had significant antimycotic activity against C. albicans and S. cerevisiae at 40 μg/disk. Although isolated from L. chagosenis, clathridine B (178) was named for its similarity to 177 [94] . Clathridine C (179), similar to 177 in the absence of substitution at C5, was isolated both from Leucetta sp. and its associated predatory nudibranch [107] . The sulfated derivative (9E)-clathridine-9-N-(2-sulfoethyl)imine (180) was isolated from L. microraphis and is presumably the condensation product of clathridine and taurine [115] . Along with naamidine I (141) and leucettamidine (176), 180 illustrates the ability of the functionalized hydantoin to undergo biosynthetic condensation with a variety of primary amines.
Interestingly a number of these naamidine and naamidine-type alkaloids have been isolated as Zn 2+ coordination complexes (Fig. 44) . The first of these complexes, described by Fattorusso, was a homodimer of clathridine (181) [114] . Further analysis of the X-ray crystal structure of 181 showed that the anionic clathridine acts as a bidentate ligand with dative bonding between both N-3 and N-8 [116] .
Subsequently the Zn 2+ complex of isonaamidine C (182) was described accompanying the isolation of preclathridine and clathridine B [94] . Mixed-ligand zinc complexes have also been isolated, including those between naamidines A and G (183-185) [108] and between isonaamidines B and D (186, 187) [87] . The purpose, if any, of these complexes is unknown although it is tantalizing to think that they act as sequestering agents. Such that in the marine environment, these organisms would be provided with adequate concentrations of zinc to charge the numerous metalloenzymes that require Zn 2+ for catalytic activity.
Category III: Leucetta 2-Aminoimidazoles
The existence of the 14-hydroxy, 14-methoxy, and 14-oxo-naamidines (143-147) suggest that the category III alkaloids may be derived from these intermediates by carbocylization onto the oxidized benzylic carbon. The first of these alkaloids, kealiquinone (188) was co-isolated with pyronaamidine from Leucetta sp. [110] Subsequently 2-deoxy-2-aminokealiquinone (189) was isolated, suggesting that 188 may be derived from 189 by hydrolysis [86] .
The kealiinines (190) (191) (192) were co-isolated with naamidines F and G from L. chagosensis [116] . This series may serve as biosynthetic precursors to 188 and 189 via further oxidation of the aromatic system. Kealiinine A was shown to be toxic to brine shrimp (LD 50 = 20 μg/mL). The further oxidized metabolites spirocalcaridine A (193) and B (194) were isolated from Fijian collections of a Leucetta sp. [117] . This metabolite presumably arises from an ipsocarbocyclization of the C-ring with concomitant oxidation of the 2-aminoimidazole core.
Category IV: Leucetta 2-Aminoimidazoles
The category IV alkaloids are oxidized in the A-ring to the 2-aminoimidazolone (Fig. 46) . It is still unclear whether the acid oxidation state of C5 is a result of a 2-aminoimidaozle epoxidation/rearrangement sequence or whether it is installed directly by the condensation of guanidine with p-hydroxyphenylpyruvate [89] .
Leucettamine B (195) was co-isolated with leucettamine A (104) and leucettamidine (176) [96] . Leucettamine C was isolated along with with N,N-dimethylnaamidine D [89] . Leucosolenamines A (197) and B (198) were isolated from specimens of Leucosolenia sp. collectind in Papua New Guinea [118] . These compounds were isolated by bioassay guided fractionation and it was further shown that 197 is cytotoxic against the murine colon adenocarcinoma C-38 cell line. While these compound share the same oxidation state in the imidazolone core, it is interesting to note that replacement of the C5 carbonyl with the N,N-dimethyl-5,6-diaminopyrimidine-2,4-dione moiety prefers the N3-C4 imine tautomer. Calcaridine (199) was co-isolated with the category III alkaloids 193 and 194 [117] .
In 2004 Crews reported the isolation and characterization of a uniquely modified imidazole alkaloid spiroleucettadine (200), from the same family of sponges [119] . Crews assigned the structure of 200 on the basis spectroscopic and chiroptical evidence. Spiroleucettadine turns out to be a noteworthy compound on the basis of its novel, highly strained 5,5-trans fused bicyclic core as well as having good antibacterial activity with an MIC of <6.25 μg/mL against Enterococcus durans. Since the publication of the proposed structure of spiroleucettadine, there have been several unsuccessful attempts at the syntheses of this natural product, the first detailed by Danishefsky [120] in 2006 and was quickly followed by Ciufolini [121] , then Watson [122] in 2007. While certainly not conclusive, based on the compelling evidence from these research groups, a revision of the structure of spiroleucettadine might be in order.
Danishefsky's key retrosynthetic step in his synthesis of spiroleucettadine would install the 5,5-bicyclic core by hydration of the cationic intermediates 201 or 202 in which it was thought that the hydration would occur from side opposite the sterically demanding benzylic group thus setting the requisite trans-bicyclic geometry (Fig. 47) . The cationic intermediates were thought to be accessible through hypervalent iodine oxidation of phenol 203. Thus Danishefsky's synthesis of spiroleucettadine began with the Knoevenagel condensation of commercially available creatinine 204 with p-methoxybenzaldehyde to give an inconsequential 3:1 mixture of Z and E olefin isomers of leucettamine C 196 (Fig. 48) .
This mixture of diastereomers was selectively Danishefsky's second-generation approach to spiroleucettadine A was attempted using an intramolecular guanidine attack on a preformed spirocyclic ester 210 (Fig. 49) . Access to the key spirocyclic ester 210 began with a sequential dialkylation of imine ester 211 under phase-transfer catalysis conditions to efficiently install the quaternary center of -amino ester 212 in excellent yield. Hydrolysis of the methyl ester was followed by Boc protection to give the Boc-amino acid 213. underwent condensation-cyclization. However, none of the desired amino hemiketal was detected, rather the unexpected acyl-transfer product 208 was the sole product of the reaction.
Danishefsky's final attempt at spiroleucettadine began with the reduction of the previously prepared acyl guanidine 207 with LiEt 3 BH to give the hemiaminal (Fig. 50) . Hydrogenolysis of the benzyl ether freed the phenol, giving 216. Oxidation of the phenol with PIFA gave the hydroxydienone which readily underwent spirocyclization to give the 5,5-bicyclic aminal 217 in an unexpectedly high yield. Extensive efforts to oxidize the hemiaminal in 217 failed to give the desired amino hemiketal in spiroleucettadine.
Ciufolini was the next to attempt the synthesis of spiroleucettadine (Fig. 51) . Similar to Danishefsky's approach, Ciufolini proposed to assemble the 5,5-bicyclic core through an analogous oxidative spirocyclization of phenol 203. Ciufolini began with the alkylation of the lithium enolate of the known tyrosine derivative 218 with p-PhSO 3 BnBr to give -amino ester 219. The N-Boc protecting group was then cleaved and the resulting N-methyl amine was subjected to guanylation using N,N -diBoc-protected isothiourea 220. Surprisingly, these reaction conditions also cleaved the methyl ester which Ciufolini attributes to the possible inadvertent introduction of moisture to the reaction conditions giving carboxylic acid 221. Methylation conditions (excess MeI, NaH) installed the requisite N-methyl group and also served to simultaneously reform the methyl ester. Treatment of the ester with aqueous KOH/MeOH induced ester hydrolysis, cleavage of the sulfonyl group, and selective mono-Boc-deprotection of the imino group of the guanidine to give 222. Cleavage of the remaining Boc group was followed by simultaneous cyclization to give the acyl guanidinium salt 223, the structure of which was assigned by HMBC correlation as having an incorrect N,N -dimethyl substitution pattern needed for the proposed structure of spiroleucettadine. In order to address the correct N-methyl substitution pattern for spiroleucettadine, Ciufolini begins with the treatment of the previously prepared intermediate 221 with TFA which removes both Boc protecting groups allowing for the spontaneous cyclization to give the acyl guanidine (Fig. 52 ). The imino group was then selectively reprotected using Boc 2 O to give 224. Selective methylation then gave 225, whose structure was assigned on HMBC correlations to have the correct methylation pattern needed for the natural product. The sulfonyl group was then removed under aqueous KOH conditions and was followed by Boc deprotection under acidic conditions to give acyl guanidinium salt 226.
Ciufolini was now ready to attempt the oxidative cyclization to form 5,5-bicyclic core. Treatment of 226 with PhI(OAc) 2 in hexafluoroisopropanol, however, gave an intractable mixture of products and none of either the desired product 200 or the hydroxydienone 227 (Fig. 53) . At this point Ciufolini attempted the oxidative cyclization with earlier phenol intermediates 225 and 223 using PhI(OAc) 2 in aqueous hexafluoroisopropanol, which formed only the corresponding hydroxydienones 208 and 228 in 8% and 95% yield respectively, which were then unreactive to cyclization. These results are consistent with Danishefsky's observations.
The most recent attempt at the synthesis of spiroleucettadine came from Watson (Fig. 54) . Beginning the stereospecific synthesis of spiroleucettadine A, treatment of commercially available D-tyrosine derivative 229 was treated with benzaldehyde dimethyl acetal in the presence of BF 3 •Et 2 O to form the cis-epimer of 5-oxazolidinone 230. Alkylation of the potassium enolate of 230 with PMBBr gives the , -disubstituted oxazolidinone 231 containing the correct stereochemistry about the newly formed quaternary center. Basic hydrolysis of the stereo-directing aminal group furnished -amino acid 232, which was selectively N-methylated. Conversion of the carboxylic acid to the methyl amide 233 was accomplished by in situ formation of the acid fluoride by DAST, followed by treatment with excess MeNH 2 . Simultaneous cleavage of the benzyl ether and the Cbz group under hydrogenation conditions gave 234, which upon exposure to cyanogens bromide underwent cyclization to give the desired key intermediate 235, albeit in poor yield. Analogous to Danishefsky and Ciufolini's observations, all of Watson's attempts to oxidatively cyclize 235 failed to produce spiroleucettadine.
With the synthetic evidence of the previous two papers by Danishefsky and Ciufolini along with their own work, Watson re-evaluated the spectroscopic data published by Crews and provided a new proposed structure of spiroleucettadine (236) (Fig. 55) . Based on density functional calculations of 13 C-NMR chemical shifts, 236 is in better alignment with experimental results than the original proposed structure 200, and should be more stable. Crews and co-workers have very recently confirmed the structure of spiroleucettadine to be that represented by structure 237 by X-ray crystallography and DFT calculations [123] .
CONCLUSIONS
The 2-aminoimidazole has proven to be a valuable pharmacophore in medicinal chemistry. In many cases, this heterocycle retains the ability to conserve the important hydrogen bond donor-acceptor pattern of a guanidine. Slight modifications of the core can generate pharmacophores with a large dynamic pK a range (~4-10). Controlling pK a helps the medicinal chemist tailor the heterocyclic core for desired pharmacokinetic profiles. Nature has exploited the 2-aminoimidazole as a natural product scaffold. Sponges of the class Calcarea have provided an interesting class of highly substituted 2-aminoimidazoles having been shown to interrogate a diverse range of biological processes. It is anticipated that the 2-aminoimidazole will provide an excellent scaffold for the preparation of high value small molecules for discovery based research and high throughput screening efforts. 
